🇺🇸 FDA
Patent

US 11311624

Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds

granted A61KA61K31/553A61K47/54

Quick answer

US patent 11311624 (Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/553, A61K47/54, A61K47/60, A61P